Introduction
An increasing number of patients with advanced coronary artery disease become suboptimal candidates for further revascularization, and continue to have symptoms despite best medical management. [1] [2] [3] [4] [5] [6] The treatment options available for these patients with refractory angina (RA) are limited to risk factor modification, antianginal medication, enhanced external counter pulsation (EECP), and novel interventional techniques including new approaches to chronic total occlusions and the coronary sinus reducer. [3] [4] [5] [6] [7] [8] Up to 15% of patients undergoing cardiac catheterization have ischaemia or angina and are suboptimal candidates for revascularization and this population is growing by up to 100 000 patients per year in the US. [1] [2] [3] [4] [5] [6] Although, previously associated with high mortality, the prognosis of RA has improved but mortality remains approximately 3-5% per year, [9] [10] [11] and resource utilization is extremely high. 10 These observations reflect the dire need for novel therapies for these patients. Cell therapy utilizing autologous CD34 þ (auto-CD34 þ ) cells is a promising therapy for RA patients. [3] [4] [5] [6] CD34 þ was the original marker used to identify and isolate endothelial progenitor cells, a cell which can generate new blood vessels in vitro and promote angiogenesis in vivo. 12, 13 In the US, the auto-CD34 þ cell therapy program was initially developed through two early phase clinical trials, which established the feasibility 14 and dose-response 15 for intramyocardial (IM) delivered auto-CD34 þ cells to improve exercise capacity. A Phase III pivotal trial was initiated 16 but terminated prematurely by the sponsor solely for financial reasons. As a result, no single trial was adequately powered to conclusively define the efficacy of this therapy. 17 Since each of these three trials enrolled nearly identical patient populations and used similar designs and outcome measures, we performed a patient-level pooled analysis to compare the efficacy and safety of auto-CD34 þ therapy for patients with Canadian Cardiovascular Society Class III or IV RA with placebo.
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Methods (SOC) group mandated by the Food and Drug Administration (FDA), respectively. Placebo patients underwent the same procedures as treated subjects including mobilization of bone marrow with granulocyte colonystimulating factor (GCSF), apheresis to collect mobilized mononuclear cells and IM injection with the exact same diluent used to suspend CD34 þ cells for the active treatment arm. [14] [15] [16] [17] [18] Because participants assigned to open-label SOC received no trial specific therapy, they did not undergo assessment of efficacy endpoints. 16, 17 The SOC arm was included only in the RENEW trial and was associated with a significantly higher major adverse cardiac events (MACE) rate as previously reported, and is therefore not included in this analysis. 17 Follow-up from the Phase I trial was censored at 6 months because patient treatment assignments were unblinded at this time point, and subsequent treatment group crossover was allowed. Complete trial datasets were obtained from the sponsor for each trial, and patient-level data was abstracted at longest available follow-up.
Definition of endpoints
Patients in each study underwent standardized exercise treadmill testing using either a Bruce (Phase I) or modified Bruce (ACT-34 and RENEW) protocol. All patients were required to experience angina-limited exercise capacity of 1-6 min (Phase I, Bruce protocol) or 3-10 min (ACT-34 and RENEW, modified Bruce), thus the change in exercise time in each trial fell at the same gradations of exercise. Total exercise time (TET) was assessed at baseline and 3-month time points in Phase I, and at baseline, 3-, 6-, and 12-months in the ACT-34 and RENEW trials. Exercise treadmill tests from ACT-34 and RENEW were interpreted and quantified by an independent core laboratory (Harvard University). Self-reported angina was collected in each study utilizing paper diaries in Phase I, an interactive voice response system daily diary in ACT-34, and an electronic tablet based capture system in RENEW, in which patients entered daily angina episodes. Angina frequency was collected at baseline, 3-and 6-month time points in each study, and also at 12-month in the ACT-34 and RENEW trials.
All-cause death, myocardial infarction (MI), stroke, and cardiovascular hospitalizations were collected to 6-months in Phase I, to 12-months in ACT-34, and to 24-months in the ACT-34 extension and RENEW studies. Events were investigator-reported in the Phase I trial, but were centrally adjudicated by an independent group in the ACT-34/ACT-34 extension, and RENEW trials.
Statistical methods
Efficacy results were analysed both as intent-to-treat (ITT) (as randomized) and as-treated populations, in which patients were analysed according to treatment actually received. Efficacy analysis excluded seven participants from the ACT34 trial, because of compliance issues at a study site, as originally reported. 15 In total, four patients randomized to auto-CD34 þ cell therapy received substituted placebo injections because of manufacturing issues with the cell product. Patients (auto-CD34 þ n = 4 and placebo n = 2) who did not receive injections, and were unblinded did not undergo follow-up efficacy assessments. Summary statistics for patient characteristics, procedures, and outcomes are presented by treatment group (auto-CD34 þ and placebo) and by trial. At each follow-up time point, within-patient changes from baseline (post-baseline) were calculated for TET and angina frequency. Continuous variables are presented using median (interquartile range) and compared using analysis of variance or Kruskal-Wallis, as appropriate. Categorical variables are presented using frequencies (percentages) and compared using the v 2 test or the Fisher's exact test, as appropriate.
Treatment effects in change for TET were tested in an analysis of covariance mixed-effects model with repeated measures, assuming an unstructured variance/covariance matrix for measurements within a patient. Change in TET was the dependent variable. The independent fixed-effect parameters were treatment group, visit, and the interaction between treatment group and visit. Trial and the individual baseline value of TET were included as baseline covariates. At each time point, least squares means and standard errors and the treatment effect (mean difference in change for TET between auto-CD34 þ and placebo groups) was estimated from the repeated measures model and reported with a 95% confidence interval and P-value. Treatment effects on angina frequency (AF) were tested using the prespecified Poisson regression as well as a negative binomial regression, both utilizing a log-linear model with repeated measures (see Supplementary material online, Appendix for detailed methology). The Kaplan-Meier rate estimates for individual MACE (MI, stroke, CVhospitalization, and all-cause death), as well as the composite, were presented for auto-CD34 þ and placebo groups through 24 months. The logrank test was used to compare the time-to-event distributions between the auto-CD34 þ and Placebo groups.
A P-value <0.05 was considered statistically significant and no adjustment was made for multiple comparisons. Statistical analyses were performed by Duke Clinical Research Institute, (Durham, NC, USA) using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results

Patient characteristics
The relative contribution of each trial to the overall analysis as well as the number of patients receiving each dose of auto-CD34 þ cells studied is shown in Table 1 . Over 50% of the patients came from the ACT-34 trial 15 with another 37% from the RENEW study. 17 Patient characteristics and medical therapy were consistent across the treatment strategies ( Table 2 ) and across trials (see Supplementary material online, Table S2 ), and are notable for a median age of 63 years, a large proportion of Caucasian males and with a high prevalence of cardiovascular risk factors, including over 50% with diabetes. These patients also had an extensive history of previous revascularization with nearly 90% of patients having undergone prior coronary artery bypass grafting and/or percutaneous coronary intervention. The use of anti-anginal therapies was also high (Table 3) . Notably, ranolazine was approved in the US midway during the conduct of the ACT-34 Phase II trial and therefore varied across trials from 0% in the Phase I trial, to 27 .4% in ACT34, to 59.8% in RENEW.
Exercise capacity
Patients randomized to placebo improved their TET by 31-50 s across the 3-to 12-month points (Table 3, Figure 1A , see Supplementary material online, Table S3 ). Patients randomized to auto-CD34 þ cell therapy improved their TET by 77-99 s, which outperformed placebo by a consistent 45-50 s throughout the 3-12 month period. Results were consistent when analysed as-treated with similar increases in treatment effect (45-53 s), findings which were statistically significant at each time point. (Table 3 and Figure 1B ).
Angina frequency
Patients in each trial, including those treated with placebo injections, reported significant reductions in angina with up to an 80% reduction in angina in the RENEW trial (see Supplementary material online, Table S4 ). Auto-CD34 þ cell therapy was associated with a statistically significant lower frequency of angina at each time point when analysed as prespecified using a Poisson regression in both the ITT and as-treated analysis ( Table 4 and Figure 2 ). Due to overdispersion observed as well as a few individual patients with high influence on the Poisson regression results, additional analyses were performed using a negative binomial regression (see Supplementary material online, Table S5 ) and also by refitting the Poisson analysis excluding three potentially influential patients (Pearson residual >20 or Cluster Cook's D >0.5) (see Supplementary material online, Table S6 ). Utilizing the more conservative, but post hoc, negative binomial analysis, Auto-CD34 þ cells were associated with a 10-20% reduction in the frequency of angina which was not statistically significant. These analyses demonstrated consistent reductions in angina, with a statistically significant reduction observed utilizing the prespecified statistical methodology agreed upon with regulators.
Dose sensitivity
To assess the efficacy of the targeted cell dose, we compared patients randomized to 1 Â 10 5 cells/kg with those randomized to placebo. Cell therapy with the dose of 1 Â 10 5 cells significantly and consistently improved both TET and AF up to 12 months with effects that were similar to those observed in the overall analysis, both when analysed as ITT and as treated (see Supplementary material online, Table S7 and S8).
Mortality and major adverse cardiac events
Compared with placebo, auto-CD34 þ cell therapy significantly decreased all-cause mortality at 24 months (12.1% vs. 2.5%; P = 0.0025) ( Table 5 and Figure 3) . Although not significant, auto-CD34 þ cell therapy was also associated with a clinically meaningful reduction in MACE (38.9% vs. 30 .0%; P = 0.14) which was driven by a reduction in all-cause death and CV-hospitalizations. The results remained robust when analysed as treated (mortality 11.8% vs 2.6%, P = 0.0038, MACE 38.2% vs. 29 .9%, P = 0.15).
Discussion
Despite the growing numbers of patients with non-revascularizable coronary artery disease, only two new therapies have been approved for the treatment of RA in the last 40 years. Ranolazine was approved 19 and EECP demonstrated improvement in time-to-ST depression but not overall exercise capacity in a RA population. 20 More recently, the effectiveness of ranolazine has been questioned. 21, 22 Given the lack of effective options, regenerative therapies, especially potent angiogenic populations, may represent a particularly attractive approach for the treatment of these patients. CD34 þ was the original cell-surface marker used to identify and isolate endothelial progenitor cells, a cell with potent in vivo angiogenic capabilities. 12, 13 In humans lower levels of circulating CD34 þ cells predict more advanced coronary disease, 23, 24 worse outcomes after MI, 25 decreased physical function both at baseline as well as change over time, 26, 27 and most compellingly, increased mortality. 28 In preclinical MI models, isolated CD34 þ cells were significantly more potent than unselected bone marrow cells, showing improvements in overall myocardial performance and regional wall motion, as well as in moderating fibrosis and increasing angiogenesis, even when CD34 þ cell dose was normalized. 13 Thus, pre-clinical as well as clinical data points to the importance of this cell population in angiogenesis and ongoing vascular repair. Although the individual studies were not powered to demonstrate a mortality benefit, a statistically significant improvement in mortality was observed in this combined patient-level analysis. While it is conceivable that the mortality difference observed is secondary to harm from placebo injections, the observed mortality in the placebo arm mirrors that observed in contemporary observations from registries, suggesting that the observed mortality benefit is more likely ascribable to benefit in CD34 þ treated patients. 10, 11 Our results at minimum definitively support the safety of this approach, adding to the large body of data in this regard. Cell therapy reduced AF compared with blinded placebo injection when analysed using the prespecified methodology agreed to with FDA regulators in a statistical analysis plan submitted prior to initiation of RENEW. Notably, this is a higher reduction than what was achieved with Ranolazine or EECP. The sensitivity of these analyses to the model used point to the difficulty of utilizing angina counts as an endpoint in clinical trials and may arise from differences in the methodologies used to collect angina across the three trials. Notably in RENEW, while patients remained blinded to treatment assignment, they were also made aware of the decision of the sponsor to prematurely terminate the trial. In RENEW, the median number of angina episodes decreased from 18 at baseline to three at 12-month followup, raising the possibility that patients abandoned their reporting efforts thereby diluting any treatment effect.
Comparisons of the high CV-hospitalization and composite MACE rates observed in the small number of patients in the SOC arm as reported in the RENEW trial 17 support the previous registry observations made in much larger patient populations regarding resource utilization in these patients when treatment options are absent. 10, 11 More importantly, we believe the wide divergence in the rates of MACE in both the placebo and cell-treated patients as confirmed in this meta-analysis (reported Kaplan-Meier rate in RENEW SOC arm 72.5% at 24 months vs. 38.9% in the placebo arm and 30.0% in the auto-CD34 þ arm) compared with those not offered full participation in a trial illustrates the unmet need for the development of novel treatments for these patients. [14] [15] [16] [17] [18] In addition, it highlights the effectiveness of blinding in these studies, adding credence to the observations regarding exercise capacity which may be impacted by knowledge of treatment assignment, and validating the choice of a fully double-blinded control arm in RA studies. Finally, it is worth noting that our results are consistent with several large meta-analyses of cell therapy in no option patients with refractory ischaemia [29] [30] [31] [32] as well as with the results of intracoronary auto-CD34 þ cells used in trials of RA, acute MI, and heart failure.
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Limitations
Patients randomized to IM placebo injections underwent stem cell mobilization and collection with daily GCSF injections and apheresis. We cannot exclude that these treatments either have a beneficial effect or impart some risk; however, it must be noted that the SOC arm in the RENEW trial had the highest MACE rate, 17 obviating concern in this regard and that the overall MACE rate in the ACT-34 study was modest and consistent with contemporaneous data in similar populations. No pre-clinical data suggest that transient mobilization of auto-CD34 þ cells in the setting of chronic myocardial ischaemia is an effective therapy. If cell mobilization into the circulation is an effective treatment option, the effectiveness of IM auto-CD34 þ is even more notable. While it is possible that the improvement in mortality observed is due to risk incurred by placebo injections, the observed mortality rate in the placebo arm is consistent with that reported in registry studies of populations that would have qualified for these trials and the mortality rate in the auto-CD34 þ groups was lower than reported in the previous observations made in similar patient populations. 11 Notably, the mortality curves continue to separate over time,
suggesting that early procedural complications were not responsible for this result. Despite the aggregate experience from three trials in this work, the numbers of clinical events remain small, and the overall analysis remains underpowered to definitively define a treatment effect on clinical outcomes. The AF data had evidence of overdispersion, nonetheless, the point estimate was consistently in favour of cell therapy with a relative risk of at least 0.8, an effect that would be highly clinically impactful.
Conclusions
A combined patient-level analysis of three sequential double-blind clinical trials enrolling Class III and IV RA patients encompassing over a decade of enrollment demonstrated consistent and durable improvements in exercise capacity, AF, and mortality. These findings suggest that had RENEW been run to completion, a viable regenerative approach to the treatment of RA might have met criteria for clinical approval. These findings point to the promise and need for additional study of this therapy, and serve as a cautionary note of the potential loss to the medical and clinical/patient communities of the premature termination of clinical studies. Given the significant unmet clinical need for these no option patients, approaches to more rapid and cost efficient appraisal of such therapies are needed. 
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